Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Armata Pharmaceuticals (ARMP) EBITDA: 2013-2018

Historic EBITDA for Armata Pharmaceuticals (ARMP) over the last 6 years, with Dec 2018 value amounting to -$1.1 million.

  • Armata Pharmaceuticals' EBITDA rose 53.45% to -$1.1 million in Q4 2018 from the same period last year, while for Dec 2018 it was -$15.9 million, marking a year-over-year increase of 1.58%. This contributed to the annual value of -$42.4 million for FY2024, which is 3.78% down from last year.
  • Per Armata Pharmaceuticals' latest filing, its EBITDA stood at -$1.1 million for Q4 2018, which was up 60.27% from -$2.8 million recorded in Q3 2018.
  • In the past 5 years, Armata Pharmaceuticals' EBITDA ranged from a high of $19.3 million in Q3 2014 and a low of -$12.0 million during Q1 2014.
  • For the 3-year period, Armata Pharmaceuticals' EBITDA averaged around -$4.8 million, with its median value being -$3.4 million (2016).
  • The largest annual percentage gain for Armata Pharmaceuticals' EBITDA in the last 5 years was 221.59% (2014), contrasted with its biggest fall of 594.75% (2014).
  • Over the past 5 years, Armata Pharmaceuticals' EBITDA (Quarterly) stood at -$2.6 million in 2014, then dropped by 13.21% to -$2.9 million in 2015, then plummeted by 303.54% to -$11.9 million in 2016, then surged by 80.07% to -$2.4 million in 2017, then skyrocketed by 53.45% to -$1.1 million in 2018.
  • Its EBITDA stands at -$1.1 million for Q4 2018, versus -$2.8 million for Q3 2018 and -$9.7 million for Q2 2018.